> Memory Pharmaceuticals has suspended a midstage trial of its Alzheimer's therapy as it addresses the FDA's request for more information on revisions to toxicology reports. Report
> The FDA has rejected Cytomedix's claim that its AutoloGel wound healing gel is equivalent to similar therapies on the market. Report
> Dr. Mauro Ferrari, a cancer nanotechnology authority, has announced the launch of Leonardo BioSystems, a new company that will focus on nanotechnology-based cancer therapeutics. Release
> Sanofi-Aventis has sold its remaining stake in Rhodia to BNP Paribas for $228 million. Report
> The Philadelphia Inquirer profiles Beijing Med-Pharm, a Chinese company that boasts a soup-to-nuts approach to biopharma. Med-Pharm says it can handle everything from clinical trials to distribution of approved pharmaceuticals. At $11.7 billion, the country's drug market is small, but growing fast. IMS Health expects the market to become the seventh-largest worldwide in three years. And companies like Med-Pharm are hoping to cash in on the explosive growth. Article
> Arbor Vita and NoNO have partnered to develop and commercialize drugs for the treatment of stroke. The R&D collaboration combines Arbor Vita's PDZ-based drug discovery platform with NoNO's expertise in the area of neurological disorders. Release
> Several drug developers are advancing therapies for Alzheimer's and unveiling data that suggests they may be of some help in averting cognitive decline. Some observers say that there could be significant new therapies for the ailment in as little as three years. That would be helpful, as a number of researchers have derided the current slate of Alzheimer's therapies as being almost useless. Article (WSJ sub. req.)
> Genta has won orphan drug status for Genasense in Australia. Report
> Bio-Rad Laboratories has completed the acquisition of Blackhawk Biosystems. Report
And Finally... A new study questions a government's panel recommendations to reduce LDL levels to a specific, low level. Article